Jiangsu Jibeier Pharmaceutical Co Ltd (688566) — Working Capital to Net Assets Ratio
Jiangsu Jibeier Pharmaceutical Co Ltd (688566) has a Working Capital to Net Assets ratio of 44.9% as of March 2026. Working capital of CN¥1.12 Billion (current assets of CN¥1.26 Billion minus current liabilities of CN¥134.31 Million) is measured against net assets of CN¥2.50 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Jiangsu Jibeier Pharmaceutical Co Ltd (688566) balance sheet quality index to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Jiangsu Jibeier Pharmaceutical Co Ltd Working Capital to Net Assets (2016–2025)
This chart shows how Jiangsu Jibeier Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 10 annual periods from 2016 to 2025. As of March 2026, the ratio stands at 44.9%, reflecting working capital of CN¥1.12 Billion against net assets of CN¥2.50 Billion CNY. Check Jiangsu Jibeier Pharmaceutical Co Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Jiangsu Jibeier Pharmaceutical Co Ltd (2016–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Jiangsu Jibeier Pharmaceutical Co Ltd from 2016 to 2025, covering 10 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Jiangsu Jibeier Pharmaceutical Co Ltd (688566) total market value.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 44.0% | CN¥1.08 Billion | CN¥2.45 Billion | CN¥1.25 Billion | CN¥177.01 Million | ▼ -5.7 pp |
| 2024 | 49.7% | CN¥1.12 Billion | CN¥2.25 Billion | CN¥1.30 Billion | CN¥185.19 Million | ▲ +1.5 pp |
| 2023 | 48.2% | CN¥920.84 Million | CN¥1.91 Billion | CN¥1.13 Billion | CN¥210.31 Million | ▼ -15.3 pp |
| 2022 | 63.5% | CN¥1.08 Billion | CN¥1.69 Billion | CN¥1.26 Billion | CN¥181.36 Million | ▼ -16.2 pp |
| 2021 | 79.7% | CN¥1.28 Billion | CN¥1.61 Billion | CN¥1.41 Billion | CN¥124.06 Million | ▼ -10.7 pp |
| 2020 | 90.5% | CN¥1.43 Billion | CN¥1.58 Billion | CN¥1.51 Billion | CN¥84.01 Million | ▲ +26.6 pp |
| 2019 | 63.8% | CN¥300.36 Million | CN¥470.46 Million | CN¥365.44 Million | CN¥65.09 Million | ▲ +4.7 pp |
| 2018 | 59.2% | CN¥211.63 Million | CN¥357.68 Million | CN¥272.89 Million | CN¥61.26 Million | ▼ -3.7 pp |
| 2017 | 62.9% | CN¥277.24 Million | CN¥440.76 Million | CN¥329.36 Million | CN¥52.12 Million | ▲ +8.0 pp |
| 2016 | 54.9% | CN¥199.42 Million | CN¥363.15 Million | CN¥281.99 Million | CN¥82.57 Million | — |